ZielBio to Present Findings from its Phase 1/2, First-in-Human Trial of ZB131
02 Jun 2023 //
PR NEWSWIRE
ZielBio to Present New Research Utility of Cancer-Specific Plectin (CSP) ZB131
17 Apr 2023 //
PR NEWSWIRE
ZielBio Appoints Alan Bash CEO as Company Advances Oncology Therapeutics
03 Jan 2023 //
PR NEWSWIRE
ZielBio Receives Orphan Drug Designation for ZB131 for Pancreatic Cancer
27 Dec 2022 //
PRNEWSWIRE
ZielBio Receives Orphan Drug Designation for ZB131
15 Nov 2022 //
PRNEWSWIRE
ZielBio to Present New Data Demonstrating Preclinical Efficacy of ZB131
12 Apr 2022 //
PRNEWSWIRE

Market Place
Sourcing Support